Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Valley City, Utah Clinical Trials

A listing of Valley City, Utah clinical trials actively recruiting patient volunteers.

RESULTS

Found (10) clinical trials

PSD502 in Subjects With Premature Ejaculation

The study will assess whether the bothersome symptoms of premature ejaculation (PE) are helped when treated with PSD502 by answering questionnaires such as the 'Premature Ejaculation Bothersome Evaluation Questionnaire' (PEBEQ) and 'Index of Premature Ejaculation (IPE) and some additional questions about premature ejaculation. The study will also measure the effect ...

Phase

4.82 miles

Learn More »

BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER

PRIMARY OBJECTIVES: I. To determine whether, in men with post-prostatectomy PSA recurrences, salvage radiation (SRT) with enhanced anti-androgen therapy with apalutamide will improve biochemical progression-free survival (bPFS) compared to SRT alone. SECONDARY OBJECTIVES: I. To assess whether molecular stratification by the PAM50 gene expression clustering will identify subsets of prostate ...

Phase

6.28 miles

Learn More »

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

PRIMARY OBJECTIVES: I. To assess whether the addition of 6 cycles of cabazitaxel to abiraterone acetate in patients with castration-resistant prostate cancer (CRPC) that have previously received docetaxel and androgen deprivation therapy (ADT) for hormone-sensitive prostate cancer (HSPC) can improve progression-free survival (PFS) compared to abiraterone acetate alone. SECONDARY OBJECTIVES: ...

Phase

9.69 miles

Learn More »

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

This research is being done because the standard treatments for prostate cancer that has returned (PSA is elevated) after surgery and/or radiation and progressed on initial hormonal therapy are not curative. Existing treatments, such as the ketoconazole used as part of this study may decrease PSA temporarily, but unfortunately the ...

Phase

9.7 miles

Learn More »

Abiraterone/Prednisone Olaparib or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

This is a biomarker preselected, randomized, open-label, multicenter, phase II study in men with metastatic castration resistant prostate cancer (mCRPC). Patients with tumors that have ATM, BRCA1 and/or BRCA2 mutations/deletions/loss of heterozygosity will be randomized in a 1:1:1 fashion to each arm. Patients with mutations in noncanonical DNA repair genes ...

Phase

9.86 miles

Learn More »

Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone

PRIMARY OBJECTIVES: I. Abnormal fluciclovine F18 ([18F] fluciclovine) uptake on visual assessment will differ by the type of metastatic lesion present (blastic, lytic, marrow, mixed). II. Maximum standardized uptake value (SUVmax) and mean standardized uptake value (SUVmean) on (18F) fluciclovine-positron emission tomography (PET)/computed tomography (CT) imaging will differ by the ...

Phase

9.86 miles

Learn More »

Rucaparib in Nonmetastatic prOstAte With BRCAness

This is a single arm, open label, phase II trial to assess efficacy of rucaparib.

Phase

9.86 miles

Learn More »

Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer

PRIMARY OBJECTIVES: I. To assess the impact of abiraterone acetate (abiraterone) and docetaxel on total quality of life between screening and month 12 of the study. SECONDARY OBJECTIVES: I. To assess PSA response rates across the entire population and compared between groups. II. To assess impact of abiraterone and docetaxel ...

Phase

9.86 miles

Learn More »

Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy

Enzalutamide is a second-generation androgen receptor signaling inhibitor that significantly prolongs survival in patients with metastatic castration-resistant prostate cancer who have received prior docetaxel chemotherapy 35,36. Enzalutamide has demonstrated activity in cells that overexpress the androgen receptor. Unlike previous androgen receptor blocker (ARB) agents, Enzalutamide does not display any agonist ...

Phase

9.86 miles

Learn More »

Radium-223 and Radiotherapy in Hormone-Na ve Men With Oligometastatic Prostate Cancer to Bone

This is a phase IIa, open label, single arm, and prospective study of hormone therapy-nave men with oligometastatic prostate cancer to the bone. The study will test if treating the primary tumor sites and 5 or fewer sites of bone-only metastasis with external beam radiation with concomitant systemic Radium-223 will ...

Phase

9.86 miles

Learn More »